1. Reconciled Rare Genetic, Women's Health, and Other Execution & Stop-Cause Profile
| Clinical Trial Metric | Verified Value | Operational Context |
|---|---|---|
| Total Phase II & III Protocols (2018 to 2026) | 10,777 | Deterministic primary MeSH and condition-keyword assignment |
| Active Concurrent Pipeline | 3,944 | Recruiting, enrolling by invitation, and active follow-up protocols |
| Completed vs Prematurely Stopped | 3,957 / 1,190 | 23.12% closed-trial attrition ratio across 5,147 closed protocols |
| Slow Accrual vs Safety & Futility Stops | 287 / 125 / 63 | Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5) |
| Physical Hospital Site Disclosure Rate | 81.6% | Named hospital campus participations vs anonymized CRO site slots |
2. Leading Consolidated Trial Sponsors Focused on Rare Genetic, Women's Health, and Other
| Sponsor Hub | Sector | Protocols | Active | Completed | FDA NDA/BLA |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | Academic / Institutional Sponsor | 379 | 195 | 88 | 0 |
| Ain Shams University | Academic / Institutional Sponsor | 277 | 60 | 134 | 0 |
| Assiut University | Academic / Institutional Sponsor | 214 | 61 | 59 | 0 |
| Cairo University | Academic / Institutional Sponsor | 214 | 44 | 76 | 0 |
| Takeda | Biopharma Industry | 192 | 63 | 95 | 63 |
| Tanta University | Academic / Institutional Sponsor | 178 | 72 | 63 | 0 |
| Yale University | Academic / Institutional Sponsor | 146 | 80 | 36 | 0 |
| Stanford University | Academic / Cooperative Group | 139 | 69 | 39 | 0 |
| Peking University People's Hospital | Academic / Institutional Sponsor | 135 | 55 | 15 | 0 |
| Bayer | Biopharma Industry | 107 | 25 | 66 | 98 |
| Mansoura University | Academic / Institutional Sponsor | 92 | 26 | 24 | 0 |
| Vanderbilt University Medical Center | Academic / Institutional Sponsor | 81 | 35 | 32 | 0 |
3. Representative Multi-Center Phase II & III Rare Genetic, Women's Health, and Other Studies
| NCT Study | Protocol Brief Title | Sponsor | Phase | Status |
|---|---|---|---|---|
| NCT07208058 | A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Kn | TJ Biopharma Co | Phase III | RECRUITING |
| NCT07614152 | The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature | Xiamen Amoytop Biotech Co | Phase III | RECRUITING |
| NCT07396480 | Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized | First Affiliated Hospital of Zhejiang University | Phase III | RECRUITING |
| NCT07707687 | Safety and Efficacy of Eculizumab in High-risk TA-TMA | First Affiliated Hospital of Zhejiang University | Phase II | RECRUITING |
| NCT07692841 | Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors | First Affiliated Hospital of Zhejiang University | Phase III | RECRUITING |
| NCT06900920 | A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia | Chia Tai Tianqing Pharmaceutical Group Co | Phase III | RECRUITING |
| NCT05997602 | To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH | Shanghai Fosun Pharmaceutical Industrial Development Co | Phase II | RECRUITING |
| NCT06927310 | The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature | Xiamen Amoytop Biotech Co | Phase III | RECRUITING |
| NCT06747949 | A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | Amgen | Phase III | RECRUITING |
| NCT07640893 | A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease | Shanghai RAAS Blood Products Co | Phase II | RECRUITING |
| NCT07309562 | The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age | Xiamen Amoytop Biotech Co | Phase III | RECRUITING |
| NCT06937944 | Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines | JHM BioPharma (Tonghua) Co | Phase III | RECRUITING |
| NCT06902558 | ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Calico Life Sciences | Phase II | RECRUITING |
| NCT06351150 | Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock | Chia Tai Tianqing Pharmaceutical Group Co | Phase III | RECRUITING |
| NCT07710248 | SG301-SC Injection Safety Study in Subjects With Primary ITP Patients | Hangzhou Sumgen Biotech Co | Phase II | RECRUITING |
| NCT07015996 | Efficacy of Tezepelumab in Peanut Oral Immunotherapy | National Institute of Allergy and Infectious Diseases (NIAID) | Phase II | RECRUITING |
Related Therapeutic Condition Hubs & Crosswalks
Compare adjacent clinical cohorts: Oncology and Hematology · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain · Immunology, Rheumatology, and Dermatology, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.